Glomerular diseases

ISN TrialWatch

Trialwatch
home

ISN TrialWatch | Jan – Feb – March 2026

IVIG Modulates Fibrosis and Stabilizes Chronic Active AMR Progression
This phase 2 randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of BI 764198, a selective oral inhibitor of the TRPC6 channel, in adults with biopsy-confirmed primary or TRPC6-related genetic focal segmental glomerulosclerosis (FSGS).
Trial of the month:

ISN TrialWatch | Special Edition

Rituximab for Relapse Prevention in Adult Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
Rituximab for Relapsing Nephrotic Syndrome in Adults. A Randomized Clinical Trial. This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of rituximab for preventing relapse in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

ISN TrialWatch | Oct – Nov – Dec 2025

IVIG Modulates Fibrosis and Stabilizes Chronic Active AMR Progression
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Chronic active antibody-mediated rejection (AMR) is the primary cause of kidney allograft loss beyond 5 years and currently has no evidence-based long-term therapy.
Trial of the month:

ISN TrialWatch | Apr – May 2025

DAPA-Tolvaptan: First trial of SGLT2 inhibition in ADPKD with background tolvaptan therapy
In this open-label, crossover trial, 27 autosomal dominant polycystic kidney disease (ADPKD) participants on stable high-dose tolvaptan (>60mg/day, >3 months, with eGFR >25 ml/min/1.73 m2) were randomized to receive dapagliflozin 10mg daily or usual care for 6-months, then crossed to the alternate arm for another 6 months, without a washout period.
Trial of the month: